Imaging AI

iCat Solutions Ltd is a medical imaging software company specializing in advanced diagnostic visualization and analysis platforms for healthcare organizations and clinicians. The company develops 2D, 3D, and 4D imaging solutions incorporating volume rendering, multiplanar reconstruction (MPR), and specialized visualization tools designed to support clinical decision-making. iCat's software integrates with PACS (Picture Archiving and Communication Systems) and broader healthcare IT infrastructure to enable efficient clinical workflows and institutional collaboration. The platform emphasizes secure data handling and interoperability, allowing healthcare professionals to share imaging studies and collaborate across teams and institutional boundaries. Products incorporate professional-grade measurement, visualization, and analysis capabilities intended for diagnostic accuracy and clinical precision. The company targets healthcare organizations, imaging centers, and clinical departments requiring robust imaging software solutions. Regulatory compliance and integration with existing healthcare IT ecosystems are core platform design elements. iCat Solutions serves a global healthcare market with solutions tailored to evolving clinical and operational requirements.

PathAI is an AI-driven digital pathology company providing cloud-native software solutions for anatomic pathology laboratories, biopharma organizations, and clinical research. The company specializes in AI-powered histopathology analysis and digital pathology workflow management. PathAI's flagship platform, AISight®, is a cloud-native, open-architecture enterprise solution that integrates case management, image management, and AI-based diagnostic tools to enable multiple histopathology use cases. The platform serves as a central hub for digital pathology workflows across academic medical centers, reference laboratories, and health systems. AISight® Dx received FDA clearance for primary diagnosis in June 2025. PathAI also offers specialized AI-assisted tools including AIM-MASH (FDA-qualified for metabolic-associated fatty liver disease clinical trials) and AIM-HI UC/IBDExplore for standardized histopathology endpoints in clinical trials. The company operates a proprietary pathologist contributor network of board-certified pathologists to support algorithm training and validation, with millions of annotations contributed. Services include BioPharma solutions for drug and diagnostic development, central laboratory operations, and anatomic pathology lab solutions. Notable partnerships include expanded collaboration with Labcorp to deploy FDA-cleared digital pathology nationwide. The company combines pathology domain expertise with machine learning to advance precision medicine, biomarker discovery, and clinical trial standardization.

Butterfly Network manufactures and distributes the iQ3, a handheld, whole-body portable ultrasound probe for point-of-care ultrasound (POCUS) applications. The iQ3 integrates advanced AI-powered diagnostic capabilities, workflow management software, and a comprehensive education suite to enable clinicians across emergency medicine, primary care, obstetrics, and specialty practices to perform real-time ultrasound assessments at the bedside or point of care. The company serves individual practitioners, health systems, hospitals, and medical education institutions. Products include the iQ3 probe (FDA-cleared), with an established installed base of 145,000+ customers globally. The iQ3 represents an upgrade path from earlier Butterfly models (iQ, iQ+); trade-in programs are offered. Key software platform: Compass AI, a POCUS management module designed to centralize ultrasound workflows across health systems. Clinical applications include obstetric gestational age assessment, lung ultrasound (B-line detection), cardiac evaluation, and emergency diagnostic imaging. The company publishes clinical evidence demonstrating impact on patient outcomes, including reduced length of stay and improved charge capture in hospital deployments. Regulatory credentials include FDA 510(k) clearance. The platform emphasizes ease of use, portability, and seamless integration into clinical workflows for both resource-constrained and academic medical environments.

Darmiyan, Inc. is a neuroscience-driven AI and medical imaging software company developing diagnostic tools for early detection and monitoring of neurodegenerative diseases, specifically Alzheimer's disease and dementia. The company's core technology leverages over four decades of pioneering brain research combined with advanced machine learning and medical image processing to analyze cellular-level changes in brain MRI scans. BrainSee, Darmiyan's flagship FDA De Novo-approved software, utilizes proprietary algorithms to quantify microscopic tissue architecture changes (voxel-level analysis) within standard clinical-grade MRI scans, enabling non-invasive early disease detection and patient-specific monitoring of therapeutic responses. The company targets three primary markets: early Alzheimer's detection in at-risk populations, objective measurement of patient response to interventions, and biomarker development for pharmaceutical drug development programs. Darmiyan's technology is designed around four core pillars: high diagnostic accuracy, non-invasiveness, seamless integration with existing MRI infrastructure, and global accessibility. The platform operates without requiring specialized imaging hardware, positioning it for broad adoption across healthcare settings. FDA Breakthrough Designation was granted to BrainSee for its potential to improve treatment of Alzheimer's disease. Third-party clinical validation has been completed in the US and Canada by independent research investigators. The company serves healthcare providers, pharmaceutical development teams, academic medical centers, and clinical research organizations pursuing precision brain health screening and monitoring solutions.

BrainSpec, Inc develops a cloud-based software platform for Magnetic Resonance Spectroscopy (MRS) analysis. The platform provides non-invasive 'virtual biopsy' capability by measuring brain metabolite concentrations at precision levels 10,000 times lower than conventional MRI. BrainSpec Core™ combines a linear combinations model post-processing backend with a user-friendly web interface for clinicians and researchers. The platform supports cross-vendor MRI compatibility, enables precision metabolite measurement, and provides automated reporting with cloud-based processing to ensure access to cutting-edge analytical algorithms. Applications include assessment of brain tumors, Alzheimer's disease, Multiple Sclerosis, and other neurological conditions. The company has developed proprietary reference databases of normal and diseased brain chemistry to streamline MRS interpretation to clinical utility standards comparable to routine blood testing. The platform is currently in the pre-market stage with FDA clearance pending. The company is accepting a limited number of pilot research sites. Over 28,000 publications document clinical applications of MRS technology.

identifeye HEALTH Inc. develops a next-generation retinal imaging platform designed for point-of-care ophthalmologic and systemic health screening. The company's core offering is an automated, intuitive platform that captures high-quality fundus images with streamlined workflow integration into busy healthcare environments. The retinal imaging system leverages non-invasive visualization of the retina—the only location in the human body where nerves and blood vessels are directly visible without intervention—to provide personalized health insights. identifeye HEALTH is developing a suite of AI-powered screening and monitoring tools to unlock advanced clinical diagnostics at the point-of-care. The platform targets healthcare facilities seeking efficient fundus imaging capture and early disease detection. The company has received recognition in digital health and medtech publications, indicating emerging market presence and clinical validation interest.

Clairity, Inc. is a Boston-based healthcare technology company specializing in artificial intelligence-driven breast cancer risk assessment. The company develops Clairity Breast, the first FDA-authorized AI platform designed to predict a woman's five-year future risk of developing breast cancer using existing screening mammograms. The platform leverages advanced computer vision and machine learning algorithms to identify risk patterns that are not visible to the human eye, enabling earlier detection and prevention opportunities. Clairity Breast integrates seamlessly into existing mammography workflows without requiring additional imaging or specialized hardware, making it accessible to health systems nationwide. The product targets women beginning at age 35 and has been incorporated into updated National Comprehensive Cancer Network (NCCN) clinical guidelines for breast cancer screening and risk assessment. The company emphasizes equitable risk assessment to improve access to life-saving early detection and prevention strategies across diverse populations. Clairity's regulatory credentials include FDA authorization for its AI diagnostic platform. The company is in a pre-launch phase, partnering with health systems across the United States to implement the solution in clinical settings.

Canon Medical Informatics develops enterprise imaging software and advanced visualization platforms for healthcare systems. Their flagship product, Vitrea® Advanced Visualization, is a cloud-ready platform designed to consolidate imaging environments, automate workflows, and enable in-house 3D imaging capabilities across cardiology, thoracic, and general radiology applications. The platform includes specialized modules such as CT VScore+ for automated cardiac calcium scoring, Open Rib for chest CT image reformation and PACS integration, and Export+ for structured data delivery and clinical documentation. Vitrea supports PACS integration, provides enterprise scalability, and delivers AI-assisted diagnostic insights to streamline radiologist workflows and reduce manual data entry. The company serves health systems, imaging centers, and enterprise hospital networks seeking to consolidate point solutions, enable advanced visualization services in-house, and improve operational efficiency. Canon Medical Informatics is part of Canon's broader healthcare IT portfolio and focuses on clinical software, imaging AI, and decision-support solutions for the radiology enterprise.

NotAlVision Inc. is a digital health company specializing in remote patient monitoring services for retinal diseases, particularly age-related macular degeneration (AMD). The company develops home-based diagnostic devices operated by patients and AI-enabled data analysis platforms to extend eye disease management from traditional clinic settings into patients' homes. NotAlVision's platform addresses the unmet diagnostic need in ophthalmology by enabling real-time, automated analysis of patient testing data through proprietary AI algorithms. The company's approach aims to improve treatment outcomes by facilitating treatment decisions that align with each patient's disease activity timing rather than pre-scheduled clinic appointments. Key clinical focus areas include early detection of dry AMD progression to wet AMD, improving real-world wet AMD treatment outcomes, and optimizing treatment timing to reduce under-treatment. The platform connects patients and physicians 24/7 through a monitoring center and includes a suite of patient-operated home-based diagnostic devices. NotAlVision targets ophthalmology practices and retinal specialists seeking to improve patient engagement, diagnostic accuracy, and clinical outcomes in AMD management. The company combines precision medicine principles with telehealth capabilities to address the acute onset and unpredictable nature of retinal disease progression.

JelloX Biotech Inc. is a Taiwan-based biotech company specializing in 3D digital pathology imaging and AI-assisted diagnostic software. The company develops Metalite, a proprietary 3D pathology analysis software platform integrated with artificial intelligence modules designed to support precision medicine diagnostics. Metalite assists pathologists in evaluating clinical tissue specimen morphology variations and identifying tumor-targeted molecular distribution patterns, thereby enhancing cancer diagnosis accuracy and supporting new drug development workflows. The company positions itself as a pioneer in 3D intelligent pathology, leveraging innovative technology to enable precise medical diagnosis and treatment planning. JelloX markets its solutions internationally, collaborating with renowned hospitals and healthcare institutions to expand its global presence. The company emphasizes rigorous scientific validation and quality compliance as core values, with a commitment to building an integrated ecosystem of digital pathology and AI-enabled medical solutions. Services include 3D pathological image analysis and cancer cell detection support for clinical laboratories and research institutions.

Theragenics Corporation is a global specialty medical device company founded in 1981 by physicists from Georgia Institute of Technology, headquartered in Buford, Georgia. The company specializes in commercial-scale radioisotope manufacturing and low-dose-rate (LDR) brachytherapy seeds for cancer treatment, with a vertically integrated operation managing isotope production, manufacturing, and global logistics. Theragenics operates a 134,000 sq ft radioisotope production facility with 14 cyclotrons enabling large-scale isotope production for therapeutic and diagnostic radiopharmaceuticals. The company's flagship brachytherapy products include TheraSeed® Palladium-103, AgX100® Iodine-125, and Cesium-131 seeds, along with innovative delivery systems such as preloaded needle trays, eye plaques, C20™ cartridges, AnchorSeed® encapsulated seeds, and stranded configurations. Theragenics also provides contract manufacturing services for radiopharmaceuticals and operates subsidiary companies offering interventional radiology and vascular surgery solutions. With over 40 years of excellence, the company has treated more than 271,000 patients worldwide and serves physicians and providers in over 40 countries, emphasizing precision, quality, and patient-centric innovation in minimally invasive cancer therapies.

Synthesis Health Intelligence Inc. develops an intelligent, cloud-native radiology platform designed to enhance workflow efficiency and reporting accuracy for hospitals, imaging centers, and teleradiology groups. The company addresses the critical radiologist shortage through comprehensive software solutions that integrate PACS replacement, reporting, speech recognition, AI integration, and image management. The Synthesis platform includes a diagnostic and enterprise image viewer (Synthesis VISION, FDA 510(k) cleared), unified worklist management, automated exam assignment, DICOM-compliant cloud archive, and advanced clinical reporting with SynthSpeech cloud-based speech recognition. The platform incorporates the proprietary Synthesis Playbook—standardized modalities, exam types, body regions, report templates, and hanging protocols—enabling seamless deployment across multiple institutions. Key capabilities include AI-based auto-impression and report corrections, breast imaging workflows, structured reporting interoperability, intelligent data normalization, and multi-tenant architecture for healthcare networks. The company integrates FDA-cleared third-party AI applications and provides built-in training, peer review, critical results tracking, and messaging. Infrastructure complies with HIPAA and PIPEDA, with platform security certified to HITRUST, SOC2, and ISO 27001 standards. Synthesis markets to imaging healthcare professionals (radiologists, technologists, administrators) and OEMs seeking cloud migration, legacy PACS overlay or replacement, and cost-effective AI deployment at scale.

MILLENSYS is a healthcare IT and business software company founded in 2008, operating from Cairo, Egypt with offices in Blairstown, New Jersey. The company delivers a unified eHealth platform ecosystem serving 14+ countries and over 49 million patients. MILLENSYS specializes in integrated clinical software solutions including Electronic Health Records (EHR), Hospital Management Information Systems (HMIS), Picture Archiving and Communication Systems (PACS), Laboratory Information Systems (LIS), Radiology Information Systems (RIS), and telemedicine platforms. The company offers enterprise imaging with vendor-neutral archive (VNA) capabilities, cloud-based PACS, teleradiology, and AI-driven diagnostic insights. MILLENSYS also provides commercial software solutions including ERP, CRM, and financial management tools for small-to-medium enterprises. Certified to international standards including IHE/HL7 and DICOM compliance, MILLENSYS serves hospitals, medical centers, clinics, and diagnostic centers with a commitment to seamless data integration, secure cloud management, and optimized operational efficiency.

Qure.AI Technologies develops FDA-cleared artificial intelligence software solutions for medical imaging interpretation and follow-up management, focused on early detection and risk stratification of lung nodules and pulmonary pathology. The platform integrates with PACS, EMR, and dictation systems to support radiologists, pulmonologists, and emergency physicians. Core offerings include qXR-LN for lung nodule detection on chest radiographs (6–10mm sensitivity), qCT LN Quant for CT-based volumetric nodule quantification with Lung-RADS and Brock score risk stratification, and qTrack for longitudinal patient follow-up management and care coordination. The company has obtained 26 FDA-cleared indications and holds 40 patents. Products address reimbursement under CMS CPT codes 0721T, 0722T, and 0727T. Qure.AI operates across 107 countries with over 200 peer-reviewed publications and abstracts. The platform serves major healthcare partners including vRad, AstraZeneca, Merck, University Hospitals Cleveland, and Sinai Chicago. The company reported $130M in capital raised and impacts 40M+ lives annually. Solutions emphasize integration into existing clinical workflows without disruption, leveraging LLM-based intelligence for contextual risk assessment beyond traditional NLP.

JLK Inc is a medical artificial intelligence company headquartered in Santa Clara, CA, specializing in AI-driven diagnostic solutions for neurological and oncological conditions. The company develops MEDIHUB, a comprehensive AI-based platform suite that processes multiple imaging modalities—including CT, CTA, MRI, MRA, digital pathology, endoscopy, X-ray, and mammography—to support clinical decision-making across stroke management and cancer detection. The MEDIHUB Stroke platform addresses the complete care continuum from acute-phase intervention to chronic-phase prognostic prediction, with integrated mobile applications enabling rapid diagnosis and treatment planning. MEDIHUB also covers dementia assessment and brain aging analysis, plus detection and analysis of 12 cancer types including prostate, breast, gastric, and colorectal cancers. JLK positions its technology as a workflow optimization tool designed to reduce door-to-treatment time in stroke management and improve patient outcomes through early, accurate disease detection. The company targets hospital systems, imaging centers, and diagnostic facilities requiring AI-powered image analysis and clinical decision support. No specific FDA 510(k) clearances, ISO certifications, or regulatory credentials are mentioned on the website.

b-rayZ AG is a Swiss AI-powered medical software company specializing in breast imaging diagnostics and workflow optimization. The company develops a modular, end-to-end platform that integrates AI technology with clinical expertise to standardize, automate, and digitalize breast diagnostic processes. b-rayZ's ecosystem addresses inefficient workflows, staff shortages, and misdiagnosis risks by delivering real-time results with automatic BI-RADS ACR and Image Quality classifications. The platform is designed to support patients throughout their entire diagnostic journey and can be seamlessly integrated into existing IT infrastructure and imaging device systems. Key capabilities include automated quality assurance checks, standardized procedures, and physician-supported decision-making. The company serves radiological networks, imaging institutes, healthcare professionals, and patients across Europe and beyond, with notable strategic partnerships including Affidea Group, Biotronics3D, SC PACS Bulgaria, and Medecom. b-rayZ holds CE marking certification and ISO 13485 compliance (DQS MED), indicating adherence to medical device regulatory requirements. The company is headquartered in Switzerland and describes itself as Swiss-made software, with products tailored for both institutional clinical efficiency and personalized patient care approaches.

Overjet is a dental AI software company providing an integrated platform for clinical decision support and administrative automation. The company develops FDA-cleared vision AI for x-ray analysis that detects disease and anatomical structures to improve diagnosis and case acceptance. Core products include Vision AI (x-ray analysis software), IRIS (AI-native dental imaging software with auto-populated templates and image enhancement), Dental Insurance Verification (automated coverage verification across 300+ payers with code-level breakdowns), and Voice AI Suite (unified clinical intelligence combining imaging insights with voice-to-text documentation and automated charting). The platform serves dentists, dental service organizations (DSOs), educators, and dental insurers. Overjet's technology streamlines clinical workflows, reduces administrative burden through automated insurance verification and charting, and improves patient understanding through AI visualizations. The company is trusted by major dental organizations including Dental Care Alliance, CoreDental, Jefferson Dental, Aligned Dental Partners, and others. Products integrate with existing dental practice management systems and consolidate imaging and AI capabilities without separate cloud storage fees. Regulatory clearance includes FDA approval for vision AI diagnostic capabilities.

GE HealthCare is a diversified multinational medical technology and digital solutions company with over 130 years of healthcare innovation history. The company develops and manufactures a broad portfolio of diagnostic imaging equipment, patient monitoring devices, anesthesia delivery systems, maternal and infant care solutions, and clinical consumables. Key product categories include CT scanners (including the recently FDA-cleared Photonova™ Spectra photon-counting CT), ultrasound systems, diagnostic ECG equipment, anesthesia machines, and contrast media. GE HealthCare operates globally with an installed base exceeding 5 million units and serves approximately 1 billion patients annually. The company has invested over $5.1 billion in R&D and product development since 2022 and leads the FDA's list of AI-enabled medical device authorizations with 110+ clearances. GE HealthCare offers integrated digital solutions including PACS, cloud-first enterprise platforms (as evidenced by the Intelerad acquisition), and clinical decision support software. The company holds FDA 510(k) clearances, CE marking, and other regulatory credentials across its device portfolio. Manufacturing, service, and support capabilities span multiple continents, supporting hospitals, healthcare systems, and clinical facilities worldwide.

Sonio is a cloud-based AI-powered ultrasound reporting software platform specializing in OB-GYN and prenatal care. The platform integrates with ultrasound machines from all manufacturers to deliver FDA-cleared and CE-marked AI diagnostics, quality control, and automated reporting workflows. Key capabilities include Sonio Detect (AI-assisted anomaly detection), automated image management with intelligent view sorting, real-time quality control verification, visual checklists for exam completeness, integrated practice analytics, and seamless connectivity to EHRs, PACS, billing systems, and external providers via HL7/FHIR/eFAX. The platform enables sonographers and OB-GYNs to standardize reporting, improve diagnostic accuracy, reduce manual data entry, and enhance prenatal care access globally. Sonio operates on secure cloud or on-premise infrastructure with SOC2 Type II, HIPAA, ISO 13485, and GDPR compliance.

Topia MedTech Limited develops wearable diagnostics and AI-powered imaging solutions for clinical use. The company's flagship products are FibriArt, a continuous ECG monitoring patch for cardiac arrhythmia detection and remote patient monitoring, and Alzevita, an AI-based MRI segmentation and volumetry software tool for brain imaging analysis. FibriArt captures medical-grade single-lead ECG signals and provides insights into heart health, including atrial fibrillation (AFib) and atrial flutter (AFL) detection, designed for cardiologists and physicians. Alzevita automates hippocampal segmentation and volumetric reporting for radiologists and imaging labs, improving workflow efficiency and delivering reproducible imaging insights for neurodegenerative disease assessment and clinical decision-making. Both products target healthcare professionals seeking data-driven diagnostic tools. The company maintains a multi-regional presence with headquarters in North Carolina (USA) and additional offices in the UK (London), India (Ahmedabad, Vadodara), Mexico, and the EU (Ireland, Spain, Portugal, Romania). Topia MedTech positions itself as advancing smart, accessible medical technology through wearable devices and AI-powered software solutions.

Liferiver Bio-Tech is a diagnostics company specializing in nucleic acid detection and molecular testing solutions. The company manufactures PCR-based diagnostic kits, automated extraction systems, and reagents for infectious disease detection across multiple pathogen categories including respiratory pathogens, sexually transmitted infections, hepatitis viruses, tumor markers, zoonotic diseases, and gastrointestinal pathogens. Primary product lines include the AutraMic mini4800 Plus automated workstation for nucleic acid extraction and PCR testing, ChinKing mini automation solution, and comprehensive real-time PCR kit portfolios. Liferiver's monkeypox detection kits are marketed for qualitative detection of monkeypox virus DNA in suspected cases. The company offers nucleic acid isolation kits (centrifuge column and AutoEX36 E variants), extraction consumables, and multiplex PCR reagents. Liferiver serves clinical laboratories and diagnostic centers globally, with product deployment across infectious disease surveillance, outbreak response, and routine patient testing. The company demonstrates regulatory compliance capabilities with product authentication support and regulatory documentation resources on their site. Manufacturing and distribution infrastructure supports both US/Canada markets and international territories, with animal-related products excluded from US sales per disclaimer.

ADLINK Technology Inc. is a global leader in embedded and edge computing, headquartered in New Taipei City, Taiwan. Founded in 1995, the company designs and manufactures hardware and software solutions that enhance edge AI capabilities for critical applications, including medical PCs, autonomous driving, IoT, and automation. With approximately 1,800 employees and recent revenue of $327.3 million, ADLINK serves over 1,600 global customers including OEMs and Fortune 500 companies. The company's portfolio includes computer-on-modules (COM-HPC, COM Express, SMARC), industrial motherboards, edge servers, rugged computing systems, and AI platforms. Key offerings include NVIDIA Jetson and RTX Embedded solutions, IIoT gateways, EtherCAT motion control systems, HMI panel PCs, and specialized platforms for medical imaging, robotics, railway, and manufacturing applications. ADLINK also provides custom design and manufacturing services tailored to high-reliability edge intelligence requirements.

Ziosoft USA Inc is a medical imaging software company specializing in advanced visualization and quantitative analysis solutions. Since 1998, the company has developed cutting-edge 3D/4D visualization and analysis platforms serving healthcare professionals and research institutions globally. The primary product is Ziostation2, a comprehensive multi-modality and multi-specialty imaging analysis platform designed to handle complex clinical demands across diverse medical specialties. Ziostation2 integrates advanced visualization capabilities with quantitative analysis tools, enabling radiologists and clinicians to process large imaging datasets with high-speed performance and superior image transmission reliability. The platform supports scalable infrastructure that integrates with existing hospital systems to consolidate workflows and reduce operational costs. Product offerings include Advanced Visualization modules, REVORAS (PhyZiodynamics), and Zioflex (Universal Image Access), which collectively address enterprise-level visualization needs. The company emphasizes customizable workflows, extensive clinical protocols, and superior computational performance. Ziosoft targets hospitals, imaging centers, and research facilities requiring sophisticated post-processing and analysis of medical imaging data across CT, MRI, ultrasound, and other modalities. The software is designed for both clinical diagnostic use and scientific research applications.

QT Imaging Holdings, Inc. (QT Ultrasound LLC) is an FDA-cleared medical technology company specializing in automated breast imaging using quantitative transmission (QT) ultrasound technology. The flagship QTI Breast Acoustic CT™ Scanner delivers high-resolution 3D breast imaging without ionizing radiation or compression, utilizing low-frequency sound waves and AI-powered lesion classification. Designed for initial evaluation of asymptomatic high-risk women and those with dense breast tissue, the system combines advanced hardware with cloud-based image analytics and tissue biomarker analysis. The platform integrates with multimodality imaging workflows via the QTI Imaging-Olea Viewer and offers non-operator-dependent, safe alternatives to mammography, tomosynthesis, and MRI for breast cancer screening and diagnosis.

HINACOM is a leading healthcare IT software company established in 2008, specializing in medical imaging information systems, telemedicine platforms, and AI-driven diagnostic solutions. The company provides enterprise-grade imaging platforms that integrate with HIS/EMR systems, enabling centralized management of medical imaging data across healthcare networks. Core offerings include PACS systems, regional imaging collaboration platforms, cloud-based digital imaging (e-film) systems, and remote consultation platforms supporting real-time diagnostic consultation, remote training, and multi-party case discussions. HINACOM's proprietary AI algorithms focus on advanced 3D image reconstruction and automated detection (e.g., pulmonary nodule detection) across multiple specialties including ultrasound, endoscopy, ophthalmology, dentistry, nuclear medicine, pathology, and cardiology. The company serves 3,000+ healthcare institutions globally with deployments across China, United States, Europe, Southeast Asia, South Asia, and MENA regions. HINACOM holds regulatory certifications including NMPA, FDA, and CE approvals.

Atomica Technology is an AI-powered digital dentistry platform founded in 2022 that provides an integrated ecosystem of hardware and software solutions for modern dental practices. The company's core offerings include the S300 intraoral scanner for high-accuracy full-arch digital scans in under 60 seconds, complemented by proprietary AI-driven software for treatment planning, implant design, guided surgery, smile design, and CAD/CAM integration. The Atomica Suite connects all digital workflows—from scanning and planning through guides, restorations, and lab handoff—into a single, cloud-based intelligent system. The platform leverages advanced 3D imaging, computer vision, and AI segmentation to deliver precision crown designs and treatment guidance. FDA and CE approved, Atomica targets dental practices worldwide seeking to improve efficiency, treatment accuracy, and patient satisfaction through seamless digital workflows.

Dicom Systems Inc. is an enterprise medical imaging software company specializing in vendor-neutral DICOM routing, image management, and digital pathology workflows. The company operates the Unifier® platform, which processes 124 billion medical images (548 million studies) annually across 650+ deployed sites worldwide. Unifier integrates DICOM routing, PACS interoperability, archiving, de-identification, and AI workflow orchestration into a unified enterprise imaging infrastructure. The platform supports radiology, teleradiology, and digital pathology environments across on-premise, cloud, and hybrid deployments. Core capabilities include real-time DICOM routing with metadata-driven rules, vendor-neutral archiving and VNA functionality, HIPAA/GDPR-compliant de-identification at metadata and pixel levels, HL7/DICOM data normalization, and AI Conductor for automated algorithm integration and prioritized study routing. The company serves hospitals, health systems, radiology providers, government/public health organizations, academic medical centers, specialized imaging providers, and clinical research organizations. Unifier achieves high-throughput performance (800,000+ studies/day, 85,735 slides/day) and supports enterprise-scale digital pathology whole-slide imaging workflows. The platform emphasizes workflow optimization, latency reduction, interoperability across multi-vendor environments, and secure data governance for clinical research and migration initiatives.

Optomed Plc is a Finnish medical technology company specializing in handheld fundus cameras and AI-powered eye-screening solutions. Founded in 2004 and based in Oulu, Optomed develops portable retinal imaging technology for early detection of eye diseases, particularly diabetic retinopathy and related conditions. The company manufactures non-mydriatic fundus cameras including the Smartscope Pro and FDA-cleared Aurora AEYE, integrated with artificial intelligence for enhanced diagnostic accuracy. Optomed's software portfolio—Avenue AI, Avenue Eye Screen, Avenue Flow, and Avenue Telemedicine—enables ophthalmologists, primary care physicians, and pediatricians to manage workflows and conduct remote eye screenings efficiently. The platform supports telemedicine consultations and oculomics analysis for disease monitoring. Optomed serves clinical settings globally through subsidiaries in China and the United States, positioning handheld retinal imaging as accessible screening for diverse patient populations in both primary and specialist care environments.

Thermidas Oy is a Finnish health technology company established in 2008, specializing in CE-approved and FDA-cleared infrared (IR) thermal imaging systems for medical diagnostics and monitoring. The company's flagship solution is the IRT-384 Tablet, an all-in-one portable thermal imaging system with integrated VistaClinic software for real-time temperature analysis and long-term treatment evaluation. Thermidas' non-invasive, radiation-free thermal imaging technology detects asymmetric body temperatures indicating inflammation, circulatory issues, and potential ulcerations. Primary clinical applications include diabetic foot ulcer prevention and monitoring, pressure injury assessment, physiotherapy evaluation, and geriatric care. The company also offers the ThIR-A615 workstation system for hospital and clinic environments, and is developing telehealth solutions for remote home monitoring. Thermidas' intuitive software, developed in partnership with university hospitals and experienced clinicians, enables healthcare professionals to quickly locate temperature anomalies and generate comprehensive diagnostic reports. The technology is currently used by major European hospitals and research institutions including NHS, King's College London, and Finnish university hospitals.

Koios Medical is a healthcare technology company that develops FDA-cleared, CE-marked AI-powered software for ultrasound image analysis, focusing on early detection of breast and thyroid cancers. The company's proprietary SmartUltrasound® platform (Koios DS™) leverages deep learning algorithms trained on over 500,000 breast lesion ultrasound images to provide clinical decision support for radiologists and sonographers. The platform assists in detecting, classifying, and characterizing suspicious lesions, reducing missed cancers by approximately 10x while improving workflow efficiency. Koios Medical operates on an annual subscription model and partners with major OEMs including GE Healthcare and Philips for distribution across 101+ installation sites in 28 countries. The company's AI-driven approach enhances diagnostic accuracy and supports billable ultrasound procedures, enabling healthcare facilities to streamline cancer detection workflows.

Ontact Health Co., Ltd. develops SONIX Health, an FDA-cleared (510(k) K240645) AI-powered echocardiography analysis workstation designed to automate cardiac ultrasound interpretation and measurement. The solution performs fully automated analysis of 81 diagnostic parameters with 98% image recognition accuracy and 91% measurement accuracy, eliminating the need for ECG input by automatically detecting heart cycles via valve motion analysis. SONIX Health operates as vendor-neutral software compatible with multi-vendor echocardiography equipment, deployable on-premise or cloud-based without requiring high-specification hardware. The platform streamlines workflow through one-touch analysis from imaging to report generation, reducing clinician workload and examination wait times while supporting training applications. The company emphasizes clinical validation through peer-reviewed publications in cardiovascular imaging journals and demonstrated deployment in hospital environments across multiple geographies. Target markets include cardiac diagnostic centers, hospital ultrasound departments, and training programs seeking to standardize and accelerate echocardiographic assessment.

Carestream Dental is a global leader in digital dental imaging systems, software, and practice management solutions serving over one million users in 100+ countries. The company specializes in intraoral sensors (RVG 6200, CS 6200 size 0), intraoral cameras (CS 1300, CS 1500), CBCT/3D imaging systems (CS 8200 3D Advance, CS 8200 3D Access), imaging plates (CS 7600), and AI-powered clinical software including Pearl Second Opinion and CS 3D Imaging Premium. Carestream Dental also provides cloud-based practice management software (Sensei Cloud), 24/7 AI-powered virtual agent support (Cassidy), and comprehensive training and learning resources. The company emphasizes HIPAA compliance, cybersecurity, and seamless integration with major practice management platforms, supporting solo practitioners, dental service organizations, and large enterprises.

Mach7 Technologies Limited is an Australian public company founded in 2007, specializing in enterprise imaging solutions for healthcare organizations. The company offers vendor-neutral archive (VNA) technology, data management, image viewing, and workflow tools that facilitate image data storage, sharing, and interoperability across multi-disciplinary imaging environments. Mach7 focuses on integrating legacy imaging systems with modern healthcare needs, providing flexibility and technology independence without disrupting existing infrastructure. The core offering is the Mach7 Enterprise Imaging Solution (EIS), which includes advanced tools like the eUnity Enterprise Diagnostic Viewer and UnityVue—a comprehensive platform streamlining the radiology process from image acquisition to reporting. These solutions enhance multi-disciplinary imaging, digital pathology integration, and cloud-based deployments. Under new leadership, Mach7 is positioning itself as a global leader in imaging data independence, emphasizing AI integration and clinician-focused workflows to improve efficiency and clinical outcomes in healthcare settings.

Bio SB, Inc. is an FDA-registered and ISO 13485:2016 certified biotechnology manufacturer specializing in research, development, production, and distribution of antibodies and detection systems for molecular pathology. The company offers IVD validated monoclonal antibodies (rabbit and mouse), detection systems (ImmunoDetector, PolyDetector), and in situ hybridization technologies (FISH, CISH) for immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), and related diagnostic applications. Bio SB also manufactures automated staining equipment (TintoStainer Plus, TintoDetector) and tissue/cell line microarrays for cancer diagnostics, microbiology, immunology, and genetics research. The company serves biomedical laboratories, research institutions, and clinical settings globally, manufactured to FDA QSR 21 CFR Part 820 cGMP and CE IVD standards.

AIQ Solutions develops TRAQinform IQ, a FDA-cleared (510(k) K233998) software medical device for quantitative assessment of treatment response heterogeneity in late-stage cancer patients. The platform analyzes serial radiographic images (PET, CT) to measure change in lesion regions of interest over time, providing oncologists with novel quantitative and spatial information to optimize therapy selection and clinical outcomes. TRAQinform IQ measures intra-patient heterogeneity through metrics such as SUVhetero, which has demonstrated superior prognostication of overall survival compared to standard-of-care methods (RECIST, PERCIST, global SUVpeak, global volume) in retrospective studies of metastatic lung cancer and lymphoma. The software integrates into existing clinical workflows via HIPAA-compliant cloud-based image upload and automated report generation. Primary users are oncologists and clinicians managing patients with metastatic and castration-resistant prostate cancer, metastatic lung cancer, and lymphoma. The company received a new Category III CPT code for lesion heterogeneity assessment. AIQ Solutions operates US offices in Madison, Wisconsin, and an international office in Perth, Australia through the Harry Perkins Institute of Medical Research.

Huma is a UK-based global digital health company providing AI-driven cloud platform solutions for healthcare organizations, pharmaceutical companies, and research institutions. The Huma Cloud Platform (HCP) is a regulated, enterprise-grade infrastructure that enables rapid development and deployment of clinical applications including remote patient monitoring, virtual care, clinical trial data capture, and population health management. The platform integrates analytics, machine learning, and AI agents to transform connected health data into actionable clinical intelligence. Huma's applications span primary care (myGP, eConsult), secondary care (Aluna respiratory, GDm gestational diabetes, eTriage emergency), clinical trials (Alcedis), and public health (population screening, CVD risk assessment). The platform holds regulatory clearances across multiple jurisdictions (FDA 510(k) Class II, MHRA Class IIb, EU MDR, TGA, CDSCO, Saudi FDA, MDSAP) and maintains ISO 13485, ISO 27001, and SOC 2 Type II compliance. Huma supports 100+ applications built by clients, serving 100+ global organizations and approximately 100 million patients. The company's integrated delivery model includes discovery, deployment, and federated scale-up phases for healthcare transformation at national scale.

Proprio manufactures Paradigm™, an FDA-cleared surgical navigation and AI guidance platform designed for intraoperative spinal surgery applications. Paradigm combines advanced sensors, computer vision, and light-field imaging to deliver real-time 3D anatomical visualization and measurement without ionizing radiation. The platform performs continuous segmental registration, adapting automatically as patient position, table, and surgical field change—eliminating the need for repeated intraoperative imaging. Key capabilities include on-demand radiation-free measurements of spinal alignment, disc height, and segmental angles; implant-agnostic guidance; and passive collection of structured surgical data throughout preoperative, intraoperative, and postoperative phases. Clinical data show approximately 1+ hour saved per surgery, 30% increase in reimbursements, 3-4x decrease in revision surgeries, and 10x reduction in radiation exposure. Proprio has received multiple FDA 510(k) clearances, including a third clearance for dynamic 3D segmental viewing. The platform generates standardized data enabling longitudinal learning across hospital systems, objective case documentation, training initiatives, and quality programs. Proprietary AI models, trained on cases from hundreds of surgeons, enable continuous system learning. Paradigm is designed to reduce reliance on intraoperative 3D imaging and mobile CT, potentially lowering long-term capital planning costs while optimizing surgical workflows and improving institutional surgical performance metrics.

Renalytix is an AI-enabled in vitro diagnostics company specializing in chronic kidney disease (CKD) management, particularly diabetic kidney disease (DKD). The company's flagship product, KidneyIntelX.dkd, combines proprietary AI algorithms with blood-based biomarker analysis, genetic data, and electronic health record integration to generate patient risk stratification scores for progressive kidney function decline. The test received FDA marketing authorization in Q2 2023 and Medicare coverage determination in June 2024. KidneyIntelX enables early identification of high-risk patients with type 2 diabetes and CKD stages 1-3b, allowing clinicians to optimize treatment targeting and resource allocation to slow or prevent disease progression. Renalytix operates CLIA-certified clinical laboratories and partners with major healthcare systems including Mount Sinai Health System, University of Michigan, and Singing River Health System. The company also provides biomarker discovery and drug development support services to pharmaceutical partners. With a focus on shifting kidney disease management from reactive treatment to proactive health optimization, Renalytix addresses a significant public health need affecting over 850 million people globally.

Sirona Medical is a cloud-native software company specializing in radiology image management, diagnostic reporting, and AI-driven workflows. The company develops Rad OS™, an integrated platform that unifies PACS (Picture Archiving and Communication System), reporting, viewer, and worklist functionality into a single browser-based operating system for radiologists. The platform leverages AWS cloud infrastructure to enable radiologists to read studies from anywhere without legacy on-premise servers or software downloads. Sirona's core offering includes: (1) PACS Archive—a fully managed AWS-backed system with 99.99% availability and no maintenance overhead; (2) Pixel-Powered Reporter—an AI-driven reporting engine using agentic AI, proprietary NLP, and a radiology-specific large language model (LLM) to auto-generate impressions and pre-draft structured reports; (3) Integrated Viewer with patented Ontology classification that organizes studies and auto-places measurements into reports; and (4) Unified Worklist aggregating multiple sites and systems with embedded AI for context prioritization. The company integrates all clinical data feeds (DICOM, HL7, speech) and employs multimodal AI capabilities including speech-to-action agentic agents that execute workflow tasks. Pixel-to-report functionality (auto-placement of findings into appropriate report sections) is noted as undergoing regulatory review. Sirona operates a business model serving radiology practices, imaging centers, and health systems. The company has raised $110M since inception, has 30+ contracted customers across 110+ integrated sites, and maintains partnerships with AI vendors (RevealDX, Koios) for specialized diagnostic capabilities such as lung cancer screening. The platform supports remote access via SpaceX Starlink and operates with HIPAA compliance on AWS infrastructure.

Therapixel is a French software company founded in 2013 specializing in artificial intelligence for medical imaging, with offices in Nice and Paris. The company develops FDA-cleared and CE-marked AI-powered decision support software for breast cancer screening and digital mammography analysis. Its flagship product, MammoScreen®, features advanced deep learning algorithms and the MammoScreen Score™ tool to assist radiologists in interpreting screening mammograms, supporting both 2D and 3D imaging. MammoScreen integrates prior exam data to enhance malignancy prediction accuracy while reducing false positives. The company has established strategic partnerships with major healthcare networks including Mayo Clinic, Nuance Precision Imaging, and RamSoft's PACS platform to expand access to its technology across healthcare settings. Therapixel won the DREAM Digital Mammography Challenge in 2017 and conducts prospective clinical studies to validate AI utility in breast cancer screening programs.

Specto Medical AG is a Swiss medtech software company founded in 2022 as a spin-off from the University of Basel. The company specializes in real-time 3D visualization software that converts CT and MRI scans into immersive virtual reality (VR) and augmented reality (AR) experiences. The platform transforms traditional 2D medical imaging into interactive 3D anatomical models, enabling surgeons and clinicians to gain instant spatial understanding of complex anatomical structures before, during, and after surgical procedures. The software supports clinical decision-making, patient education, and surgical planning with FDA clearance and full CE certification. Primary applications include cranial neurosurgery, brain aneurysm and tumor procedures, and complex anatomical case planning. The company offers seamless DICOM integration and volume rendering technology with lightning-fast processing times and anatomically accurate visualizations.

YorLabs is a medical device manufacturer specializing in advanced diagnostic imaging solutions for interventional cardiology and electrophysiology procedures. The company develops ultraportable, handheld intracardiac echocardiography (ICE) systems powered by artificial intelligence. YorLabs' flagship ICE platform features a zero-footprint design, single-operator controls, and wireless connectivity to streamline image-guided therapy workflows. The system addresses critical inefficiencies in existing ultrasound platforms by reducing cognitive overload, procedural complexity, and workflow delays while lowering barriers to device adoption in interventional settings. Founded in 2015 and based in Beaverton, Oregon, YorLabs combines expertise from major technology and healthcare firms to deliver portable diagnostic imaging with enhanced accuracy and clinical usability.

Body Vision Medical is a commercial-stage medical device company specializing in AI-powered imaging solutions for lung cancer detection and intervention. The company's flagship product, the LungVision® system, transforms standard 2D C-arm X-ray images into advanced 3D intraoperative imaging for enhanced navigation during endobronchial biopsies. Utilizing proprietary AI Tomo® technology, LungVision corrects for CT-to-body divergence and enables tool-in-lesion confirmation, improving diagnostic yield from traditional 55-75% to approximately 90-95% for small pulmonary lesions. The system delivers superior economics with lower total cost of ownership than robotic alternatives, reduced radiation exposure (1/5 of 3D C-arms), and accessibility worldwide. Founded in 2014 by engineers experienced in electromagnetic navigation bronchoscopy, Body Vision empowers pulmonologists and thoracic surgeons with real-time, high-precision navigation for biopsy and localized therapy delivery. Recognized as a Top Medtech Startup in 2023.

Hermes Medical Solutions is a Sweden-based molecular imaging software company founded in 1976, pioneering innovations in nuclear medicine and molecular imaging. The company's flagship product, Hermia, is a comprehensive vendor-neutral software platform designed for nuclear medicine and molecular imaging departments. Hermia enables healthcare professionals to visualize, process, analyze, report, and archive imaging data from PET, SPECT, CT, and MRI modalities. The platform streamlines clinical workflows, provides advanced quantitative reconstruction tools (including SUV SPECT), and supports personalized dosimetry for theranostic applications. Hermia serves approximately 30,000 users across 70 countries and is used by university hospitals and healthcare providers globally. The software suite supports all clinical molecular imaging specialties and integrates seamlessly with existing hospital IT systems and DICOM-compliant equipment, regardless of manufacturer. Hermes has achieved regulatory clearances including FDA approval and CE marking, with recent ARTG listing in Australia.

Brainreader is a Danish medtech company specializing in AI-powered medical imaging software for quantitative brain MRI analysis. The company's flagship product, Neuroreader®, is FDA-cleared and CE-marked software that automates brain volumetric analysis from routine MRI scans. Neuroreader® quantifies 83 brain structures and identifies subtle atrophy patterns invisible to the human eye, delivering actionable insights within 10 minutes. The software supports clinicians in detecting neurodegenerative diseases including Alzheimer's disease, traumatic brain injury, and epilepsy-related changes. It integrates seamlessly into existing clinical workflows via PACS or web upload with a pay-per-use licensing model, requiring no additional hardware. The platform generates objective, reproducible volumetric data with percentiles and Z-scores to enhance diagnostic confidence and support longitudinal disease progression monitoring.

Lords Mark Industries Ltd. is a diversified Indian conglomerate based in Mumbai, founded in 1998, with 27+ years of experience in healthcare, diagnostics, renewable energy, and sustainable solutions. Through its LordsMed division, the company manufactures GMP-WHO compliant in vitro diagnostics (IVD) and medical devices including rapid diagnostic kits, serology tests, biochemistry analyzers, and IVD instruments. The company operates a 20,000 sq ft advanced manufacturing facility and is developing AI-based diagnostic solutions, including breast cancer detection technology in collaboration with CMET. Beyond diagnostics, Lords Mark produces N95 masks, face shields, nitrile gloves, hand sanitizers, and other infection control products. The company is recognized by DGS&D as a best quality supplier and serves government and global healthcare markets.

Perimeter Medical Imaging AI is a medical technology company specializing in intraoperative optical coherence tomography (OCT) imaging systems enhanced with artificial intelligence for cancer surgery guidance. The company's FDA-cleared Perimeter S-Series OCT and next-generation B-Series OCT with ImgAssist AI software provide real-time, cellular-level margin visualization during breast-conserving surgery and other oncologic procedures. These systems enable surgeons to identify residual tumor tissue and assess surgical margins with unprecedented clarity, reducing re-excision rates and repeat surgeries. Perimeter's technology leverages advanced optical imaging and machine learning algorithms to deliver actionable intraoperative insights, helping surgical teams close with confidence while improving patient outcomes and lowering healthcare costs. The company operates from Dallas, Texas with headquarters in Toronto, Canada.

Cyted Health is a Cambridge-based biotechnology company specializing in gastrointestinal molecular diagnostics for early detection and monitoring of esophageal conditions. Founded in 2020 as a University of Cambridge spinout, the company develops non-endoscopic diagnostic platforms that enable minimally invasive cell collection from the esophagus. The flagship product, EndoSign®, is an FDA-cleared capsule sponge device that provides safe, accessible esophageal sampling with full tissue coverage, significantly improving patient comfort and access compared to traditional endoscopy. Cyted Health combines proprietary biomarker discovery with AI-driven diagnostic tools to detect Barrett's Esophagus, esophageal neoplasia, and early-stage esophageal cancer. The company has completed over 35,000 tests through the UK National Health Service and operates CLIA-accredited laboratories in both the UK and US, serving healthcare systems with evidence-based screening and surveillance solutions for gastrointestinal malignancy prevention.

CorTechs Labs is a SaaS-based medical imaging software company specializing in AI-powered quantitative analysis of brain and oncological imaging. The company develops advanced algorithms for automated brain segmentation, volumetric analysis, and lesion quantification across MRI, CT, and PET modalities. Their solutions enable clinicians to detect and monitor neurodegenerative diseases (dementia, Alzheimer's, multiple sclerosis), brain tumors, and prostate cancer with improved diagnostic confidence and efficiency. CorTechs' flagship NeuroQuant® platform has processed over 2 million brain scans across 1,500+ medical institutions in 44 countries, providing radiologists with rapid, objective measurements for disease progression tracking and comparative analysis against normative databases. The company also offers OnQ™ Prostate for prostate MRI analysis and specialized tools for lesion surveillance and post-operative assessment. Solutions integrate with major OEM imaging platforms (GE, Siemens, Philips, Canon) and are supported by Category III CPT codes for reimbursement.

Rapid AI develops deep clinical artificial intelligence software for medical imaging analysis, specializing in neurovascular, cardiac & vascular, and radiology applications. The company's Rapid Enterprise™ Platform delivers FDA-cleared clinical decision support modules that enhance diagnostic confidence and streamline workflows across 2,500+ hospitals in 100+ countries. Core offerings include AI-driven triage, localization, quantification, characterization, and 3D visualization capabilities for stroke (hemorrhagic and ischemic), aneurysm, pulmonary embolism, and general radiology cases. The mobile app enables real-time alerts, case collaboration, DICOM viewer integration, EMR connectivity, and procedural workflow initiation. Rapid AI products include Lumina 3D (advanced 3D rendering and analysis, named to TIME's Best Inventions 2025), Navigator Pro (radiology workflow prioritization), and Rapid Insights (custom analytics). The company has received 30 FDA-cleared modules and maintains extensive clinical validation: 700+ peer-reviewed publications, 25+ clinical trials, 11 NEJM publications, and 17.5 mean impact factor. Processing 20,000+ daily scans, Rapid AI serves stroke centers, trauma departments, cardiac services, and life sciences organizations conducting clinical trials. The platform supports interoperability with third-party healthcare systems and EMRs, enabling cross-disciplinary deployment of AI decision support.

Activ Surgical is a Boston-based digital surgery company specializing in hardware-agnostic surgical software and intraoperative imaging technologies designed to enhance visualization and reduce surgical errors. The company's flagship product, ActivSight™ Intelligent Light, is FDA-cleared and integrates with existing laparoscopic and robotic surgical systems to provide real-time visualization of blood flow and tissue perfusion. ActivSight offers surgeons critical physiological insights invisible to the naked eye through dye-free ActivPerfusion™ and ActivICG™ imaging modes. The patent-protected ActiveEdge™ platform leverages augmented reality, artificial intelligence, and machine learning to improve intraoperative decision-making and address preventable surgical complications. Activ Surgical has achieved significant milestones including the world's first autonomous robotic surgery of soft tissue and CE Mark approval. With $87.5 million in funding, the company operates pilot sites in major U.S. hospital networks, addressing the critical clinical need that preventable surgical errors contribute to over 400,000 deaths annually in the U.S.

DESKi develops HeartFocus, an FDA-cleared AI-powered ultrasound software platform that enables clinical-grade cardiac imaging (echocardiography) across diverse care settings without requiring specialized training or dedicated echo labs. The platform combines real-time 3D guidance, on-image AI overlay, auto-recording with quality validation, and live reference examples to help primary care clinicians, nurses, emergency departments, and cardiology teams acquire all ten standard echocardiographic views at diagnostic quality. HeartFocus integrates with DICOM/PACS systems and maintains HIPAA compliance. Clinical evidence published in JACC: Advances demonstrates that novice users, including nurses without prior ultrasound experience, achieved diagnostic-quality imaging across 100% of patients. The company targets primary care, acute care, cardiology, and medical education segments. DESKi has partnered with Butterfly Network for US commercial launch and offers the POCUS HeartFocus Certification—a first-of-its-kind program for AI-guided cardiac imaging. The solution addresses critical gaps in cardiac imaging access, particularly in rural and underserved communities, and supports scalability of cardiac care delivery across the care continuum.

Calla Health Foundation is a medical device company focused on improving women's access to cervical cancer prevention and screening, particularly in low-resource settings. The organization develops portable, affordable diagnostic imaging technologies and AI-driven decision support systems designed to democratize gynecological examination and cancer prevention. Their product suite includes the Pocket Colposcope (a portable, low-cost video colposcope for cervical tissue examination), the Callascope (a speculum-free cervical imaging device enabling self-screening or provider-assisted insertion), and CARE (an AI algorithm for cervical pre-cancer risk assessment). The company's innovations enable midwives and community health workers to perform point-of-care screening and "see-and-treat" management paradigms without requiring traditional hospital infrastructure or specialized physician expertise. FDA-cleared and clinically validated in multiple low- and middle-income countries.

Canfield Scientific is a global leader in medical imaging systems, software, and clinical research services founded in 1986. The company specializes in advanced 3D and 2D imaging solutions for dermatology, plastic surgery, and aesthetic medicine practices. Core offerings include the VISIA complexion analysis system (skin assessment and hyperpigmentation detection), VECTRA whole-body 3D imaging platforms (body mapping and surgical planning), VEOS portable dermoscopy systems, D2 dermoscopy software, and IntelliStudio software suites for clinical documentation and patient communication. Canfield serves pharmaceutical, biotechnology, cosmetic, and healthcare sectors globally through a network of partners in over 50 countries, providing integrated imaging documentation, clinical analysis services, and AI-assisted diagnostic tools to support treatment planning and patient outcomes.

EVOQ Technologies is a medical device manufacturer specializing in wearable biosensor technologies for early detection of retinal and neurological diseases. Based in Henderson, Nevada, the company develops functional diagnostic platforms that detect disease dysfunction before structural changes appear on imaging. Their proprietary smartphone-based electrophysiology systems and cloud-connected wearables enable accessible, cost-effective testing in clinic and home settings. EVOQ's function-first approach targets underdiagnosis of early retinal diseases (particularly age-related macular degeneration and diabetic retinopathy), delivering diagnostic-as-a-service solutions to ophthalmologists, researchers, and healthcare providers. The SightGard™ cloud platform integrates longitudinal data with AI-ready analytics to support early intervention and improved patient outcomes.

Hamamatsu Photonics K.K. is a global leader in optical and photonic technologies with significant presence across France, Belgium, Switzerland, and Spain through its subsidiary Hamamatsu Photonics France, established in 1985. The company operates as a comprehensive supplier of advanced imaging and photonic solutions for medical, scientific research, and industrial applications. Core product portfolio encompasses over 15,000 items including scientific cameras (CCD/CMOS, InGaAs), optical sensors, photodiodes, light sources, laser systems, and spectroscopy equipment. Specialized medical applications include X-ray imaging systems, endoscopy visualization systems, and diagnostic imaging platforms. The company also supplies optoelectronic components, miniaturized spectrometers, and particle physics detectors for research institutions and healthcare facilities. With 80+ technical experts, Hamamatsu provides customized support, pilot-line manufacturing services, and rapid distribution across European and Mediterranean markets, emphasizing technical expertise and logistics efficiency.

Forus Health is a medical technology company founded in 2010 and based in Bengaluru, India, specializing in advanced ophthalmic imaging devices, AI-enabled retinal imaging solutions, and cloud-based telemedicine platforms. The company manufactures a comprehensive range of portable and desktop fundus cameras for adult and neonatal retinal screening, auto-refractometers for refractive assessment, and visual function testing systems. Forus Health's flagship 3nethra product line includes non-mydriatic and mydriatic digital imaging cameras designed for high-resolution retinal diagnostics. The company offers proprietary AI diagnostic solutions (FH-POISE Insights) that detect diabetic retinopathy, glaucoma, age-related macular degeneration, cataract, cardiovascular disease, hypertensive retinopathy, and dry eye conditions. Digital health platforms—FH TeleCare, FH TeleEye, and FH TeleOpticals—enable remote consultation and screening for distributed healthcare delivery. With installations in 75+ countries and impact on over 20 million lives, Forus Health addresses preventable blindness and vision loss, particularly in underserved regions. The company holds CE, FDA 510K, CDSCO, ISO 13485, ISO 27001, and HIPAA certifications.

Viz.ai is an AI-powered care coordination platform that leverages over 50 FDA-cleared algorithms to analyze medical imaging data and detect suspected diseases in real time. The company's flagship product, Viz.ai One®, autodetects conditions across multiple therapeutic areas including neurovascular disease, vascular conditions, cardiac imaging, trauma, and general radiology. The platform integrates specialized suites—Viz Neuro, Viz Cardio, Viz Vascular, Viz Trauma, and Viz Radiology—designed to accelerate diagnosis, streamline clinical workflows, and facilitate faster treatment decisions in acute care settings. Deployed in over 1,700 hospitals and health systems across the U.S. and Europe, Viz.ai's technology processes CT scans, EKGs, echocardiograms, and other imaging modalities to deliver automated assessments and real-time alerts to clinicians via mobile and desktop devices. The platform also supports life sciences partnerships with pharmaceutical and medical device companies for clinical trial optimization and disease-specific research applications.

KOELIS is a France-based medical technology company specializing in MRI-ultrasound fusion imaging solutions for prostate cancer diagnosis, biopsy, and treatment. The company develops the KOELIS Trinity® System, an integrated mobile fusion imaging platform that combines 3D ultrasound with advanced imaging technology to provide millimetric accuracy in needle guidance during prostate interventions. Core proprietary technologies include OBT Fusion® (organ-based tracking that records biopsy core locations), 3D Ultrasound with automatic compensation for prostate and patient movement, and the 2nd Look option for comprehensive lesion evaluation and active surveillance. KOELIS also offers PROMAP-FT software for needle-based therapy guidance and specialized ultrasound probes. Operating in over 30 countries across North America, Europe, and Asia, the company has enabled precision prostate care for over 350,000 patients worldwide. KOELIS collaborates with leading academic medical centers and hospitals to advance personalized prostate cancer management and aims to democratize access to fusion-guided biopsy technology.

Pearl Inc. is a dental AI software company providing FDA-cleared diagnostic and practice management tools for dental clinics globally. The company develops artificial intelligence solutions that analyze 2D X-rays and 3D CBCT imagery to support radiologic diagnosis, enhance patient communication, optimize clinical workflows, and improve revenue cycle management. Pearl's core products include Second Opinion (pathology detection in dental X-rays), Second Opinion 3D (CBCT analysis for specialists and general dentists), Practice Intelligence (data analytics for practice growth), Precheck (automated insurance verification and cost estimation), Calibrate (AI-guided clinical training), and Pearl Voice (ambient voice AI for clinical documentation and periodontal charting). The platform integrates with 40+ dental practice management and imaging systems including Eaglesoft, Dentrix Ascend, Dolphin, Carestream, Romexis, Vatech, Apteryx, and others. Pearl serves over 23,000 dental practices across 120+ countries and holds 26+ regulatory clearances. The company is FDA-cleared for diagnostic support workflows and claims to help practices increase treatment acceptance by 30%, detect 37% more disease, deliver 24% more care, save 20+ hours per week in operational time, and boost monthly production by $30K. Target markets include general dental practices, specialists, dental schools, and DSO networks. Pearl positions itself as dentistry's leading AI platform with emphasis on clinical validation, transparent reporting, and seamless EHR/imaging system integration.